Trial Profile

A first in man clinical trial of AX-2402

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 29 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AX 2402 (Primary)
Indications Rett syndrome
Focus Adverse reactions; First in man

Most Recent Events

12 Mar 2026 According to the ProQR Therapeutics Media Release, the company has an objective to initiate first-in-human clinical testing of AX-2402 in 1H 2027.
17 Mar 2025 New trial record
13 Mar 2025 According to the ProQR Therapeutics Media Release, company anticipates to initiation and topline readouts in 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com